Study of Efficacy and Safety of CVAA489 in Hypertensive Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 115 participants.

Also called NCT02062645

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 115 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02062645
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02062645. Allocation not applicable; no masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2017-03-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
Condition
Essential Hypertension
Intervention (Drug)
amlodipine/valsartan
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02062645
Content hash
93fd9c861f18381746a8ac85f24de7af19ddf49986d012768fbef20811cafcde